Viridian Therapeutics Inc (NAS:VRDN)
$ 12.34 0.74 (6.38%) Market Cap: 787.57 Mil Enterprise Value: 347.92 Mil PE Ratio: 0 PB Ratio: 2.06 GF Score: 46/100

Q4 2022 Viridian Therapeutics Inc Earnings Call Transcript

Mar 08, 2023 / 01:00PM GMT
Release Date Price: $29.47 (-10.48%)
Operator

Welcome to the Viridian Therapeutics Fourth Quarter and Full Year 2022 Conference Call. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to hand the floor over to Ms. Louisa Stone, Manager of Investor Relations at Viridian. Please go ahead.

Louisa Stone

Thank you, and welcome, everyone, to our fourth quarter and full year 2022 conference call. The press release reporting our financial results is available on the Investors page of our corporate website at www.viridiantherapeutics.com. Joining me on the call this morning are Scott Myers, our President and Chief Executive Officer; Kristian Humer, our Chief Financial and Business Officer; Dr. Deepa Rajagopalan, our Chief Product and Strategy Officer; and Todd James, Senior Vice President, Corporate Affairs and Investor Relations.

Before we begin, I would like to remind everyone that this conference call and webcast will contain forward-looking statements regarding our financial outlook, in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot